论文部分内容阅读
目的探讨妥洛特罗贴剂联合孟鲁司特治疗婴幼儿毛细支气管炎的临床疗效。方法将96例毛细支气管炎患儿按照随机双盲的方法分为对照组和治疗组,各48例。两组患儿均给予氧疗、抗病毒、平喘、祛痰等常规治疗,治疗组在此基础上给予妥洛特罗贴剂外用联合孟鲁司特口服,连用7d。观察两组患儿在主要症状及体征方面缓解(或消失)的时间。结果对照组与治疗组总有效率分别为72.92%,95.83%,治疗组总有效率明显高于对照组,差异具有统计学意义(P<0.05);治疗组患儿咳嗽、喘憋及肺部哮鸣音消失时间均短于对照组,两组比较具有统计学意义(P<0.05)。结论妥洛特罗贴剂联合孟鲁司特治疗毛细支气管炎可明显改善主要临床症状及体征,总有效率高,依从性好,且未见明显不良反应,值得临床推广。
Objective To investigate the clinical efficacy of tulobuterol and montelukast in the treatment of infantile bronchiolitis. Methods Ninety-six children with bronchiolitis were randomly divided into control group and treatment group according to a randomized double-blind method, 48 cases in each group. Two groups of children were given oxygen therapy, antiviral, antiasthmatic, expectorant and other conventional treatment, the treatment group on the basis of the application of trastuzumab topical montelukast oral administration, once every 7d. To observe the two groups of children in the main symptoms and signs of remission (or disappear) time. Results The total effective rate of the control group and the treatment group was 72.92% and 95.83% respectively. The total effective rate of the treatment group was significantly higher than that of the control group (P <0.05). The cough, wheezing and lungs Wheeze disappeared less than the control group, the two groups was statistically significant (P <0.05). Conclusion The combination of tulobuterol and montelukast in the treatment of bronchiolitis can significantly improve the main clinical symptoms and signs, the total effective rate, good compliance, and no obvious adverse reactions, is worthy of clinical promotion.